Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

4D Molecular Therapeutics (FDMT) EPS (Weighted Average and Diluted) (2021 - 2025)

4D Molecular Therapeutics (FDMT) has disclosed EPS (Weighted Average and Diluted) for 5 consecutive years, with -$1.01 as the latest value for Q3 2025.

  • On a quarterly basis, EPS (Weighted Average and Diluted) fell 27.85% to -$1.01 in Q3 2025 year-over-year; TTM through Sep 2025 was -$3.75, a 31.58% decrease, with the full-year FY2024 number at -$2.98, down 15.5% from a year prior.
  • EPS (Weighted Average and Diluted) was -$1.01 for Q3 2025 at 4D Molecular Therapeutics, down from -$0.98 in the prior quarter.
  • In the past five years, EPS (Weighted Average and Diluted) ranged from a high of -$0.24 in Q3 2023 to a low of -$1.01 in Q3 2025.
  • A 5-year average of -$0.77 and a median of -$0.82 in 2021 define the central range for EPS (Weighted Average and Diluted).
  • Peak YoY movement for EPS (Weighted Average and Diluted): soared 69.62% in 2023, then tumbled 229.17% in 2024.
  • 4D Molecular Therapeutics' EPS (Weighted Average and Diluted) stood at -$0.9 in 2021, then increased by 7.13% to -$0.84 in 2022, then rose by 8.33% to -$0.77 in 2023, then dropped by 16.88% to -$0.9 in 2024, then dropped by 12.22% to -$1.01 in 2025.
  • Per Business Quant, the three most recent readings for FDMT's EPS (Weighted Average and Diluted) are -$1.01 (Q3 2025), -$0.98 (Q2 2025), and -$0.86 (Q1 2025).